Conversely, PPARγ ligands enhance the efficacy of antitumoral drugs in ERα-positive breast cancer cells [29], highlighting the clinical value of these compounds in the adjuvant therapeutic strategies for breast cancer patients. This evidence concerns the gene PPARG and breast carcinoma.